In short: "I've taken a position in the ARKG biotech fund." A new starter position taken because biotech indices have "either bottomed or broken higher on the charts" after ~7–8 years out of favor, with global biotech fund flow up 73% year-over-year; he isn't a biotech expert, so he's using the ETF to get exposure to a turning sector while AI-driven drug discovery could spill over.
ARKG is a fund that owns a basket of biotech and gene-medicine companies. The whole sector has been unloved for roughly seven or eight years, so the stocks are cheap — and Polomny says the charts have finally stopped falling and started turning up, with money flowing back into biotech (fund inflows up 73% versus a year ago). He freely admits he's no expert in individual drug stocks, which is exactly why he buys the ETF: it's a low-effort "starter" way to own the sector's recovery without having to pick the one winning drug. His extra angle is that AI could speed up drug discovery, giving biotech a fresh tailwind. A small position in a bombed-out, turning sector — a "taste," not a big bet.
5:52I talked about biotech in my last video. I've taken positions. I probably might take individual stock positions inside the portfolio. We have a drug company. It's not necessarily a biotech, but we do have a drug company that's one of the best performers in the portfolio. But I've taken a position in the ARKG biotech fund.
In short: Took a small starter position in the ARK genomic ETF as it broke out — "more of a momentum trade… I just want to get a leg into it." Becoming interested in bombed-out biotech/healthcare (an 11-year downtrend vs QQQ looking to turn, the "silver tsunami" demographic); not a "big Cathie Wood fan" and may just play the sector via ETFs while he researches.
ARKG is a fund (an ETF — a basket you buy like a single stock) that holds genomics and biotech companies. That whole sector has fallen for about 11 years and badly lagged big tech (the QQQ), but the chart now looks like it's bottoming and starting to break upward.
Polomny, a generalist who admits he's "not a biotech analyst," bought a small starter position purely because it was breaking out — "a momentum trade… just to get a leg into it" — and to force himself to start researching the area. The bigger idea is the "silver tsunami": an aging population that needs more drugs and healthcare, a long-ignored, out-of-favor sector that could turn. He's not endorsing fund manager Cathie Wood; he just wants cheap exposure to a sector he thinks is turning while he digs deeper.
54:12Again, as a generalist investor, I'll be honest. I just took a position already in the ARKG, the ARK Invest genomic ETF, just to get a position because that was breaking out to the upside. That's more of a momentum trade. I just want to get a leg into it. And I'm going to be doing more investigation.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.